Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: Comparison with other diabetes prevention trials

Cardiovascular Therapeutics

Volumn 28, Issue 2, 2010, Pages 124-132

  Krum, Henry ^a   McMurray, John J V ^b   Horton, Edward ^c   Gerlock, Teresa ^d   Holzhauer, Bjoern ^d   Zuurman, Lineke ^d   Haffner, Steven M ^e   Bethel, M Angelyn ^f,g   Holman, Rury R ^f   Califf, Robert M ^g  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c HARVARD UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Impaired glucose tolerance; Nateglinide; Prevention; Valsartan

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; PLACEBO; TRIACYLGLYCEROL; VALSARTAN;

ADULT; ANAMNESIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYCLOHEXANES; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; PHENYLALANINE; PREDIABETIC STATE; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; VALINE;

EID: 77749255400     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00146.x     Document Type: Article

References (16)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 : 229 234.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000 321 : 405 412.
3. Skyler JS, Bergenstal R, Bonow RO, et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009 32 : 187 192.
4. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005 2 : 9 15.
5. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR. NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 2008 156 : 623 632.
6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006 23 : 469 480.
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 : 2735 2752.
8. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344 : 1343 1350. (Pubitemid 32378388)
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
10. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet 2008 371 : 1783 1789.
11. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 2004 47 : 1519 1527.
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002 359 : 2072 2077.
13. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009 373 : 2215 2221.
14. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 342 : 145 153.
15. Fox KM EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 362 : 782 788.
16. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004 351 : 2058 2068.